2024-08-20 07:32:03
” data-script = ” >
This announcement comes against the background of frequent debates on the dependence of the French, and more Western, pharmaceutical industry on other actors, especially Chinese and Indian.
French pharmaceutical company Pierre Fabre wants to sell one of its sites, located in Haute-Savoie and specialized in research, to the Indian group Jubilant Pharmova, it announced on Monday. “Pierre Fabre Companies are entering into exclusive negotiations with Jubilant Biosys Limited for the acquisition of their Saint-Julien-en-Genevois research site», announced the French team in a press release.
This site, which has thirty employees, explores research methods for various categories of treatments – biological drugs and synthetic proteins – in cancer. The sale takes place in an area where the laboratory wants to focus on other methods against cancer and brings together its research groups near its headquarters in Toulouse.
Pierre Fabre kept a small tree for 5 years
Jubilant Biosys is a subsidiary of an Indian group, Jubilant Pharmova, with which other pharmaceutical groups share various research activities. These groups, called CROs for “contract research organization» (contract research company), has become an important part of the pharmaceutical industry and includes many Indian companies.
The service announced on Monday, the amount of which was not disclosed, provides for “acquisition of the site, its 35 employees, buildings and equipment and current research activities», Explains Pierre Fabre, who will keep a small tree for five years.
This announcement comes against the background of frequent debates on the dependence of the French, and more Western, pharmaceutical industry on other players, especially Chinese and Indian. The French generic giant Biogaran, owned by Servier Karun, will probably be sold and several Indian groups are among its potential buyers.
#Laboratory #Pierre #Fabre #plans #sell #research #site #HauteSavoie #Indian #group